autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells

The drug "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells" is a type of chimeric antigen receptor T cell (CAR-T) therapy. This is an autologous cell therapy where a patient's own T cells are genetically modified to express a chimeric antigen receptor that targets CD19, a protein found on the surface of B cells. ## Structure and Components This specific CAR-T product contains: - CD19-targeting receptor (recognizes CD19 on B cells) - CD28 co-stimulatory domain (provides activation signals) - CD3zeta signaling domain (triggers T cell activation) - EGFRt (truncated epidermal growth factor receptor) as a safety switch - Tcm-enriched (central memory T cells) composition The therapy is designed to direct the modified T cells to CD19-expressing tumor cells, particularly in B-cell malignancies such as leukemias and lymphomas. The inclusion of the EGFRt component serves as a safety mechanism that allows for potential depletion of the CAR-T cells if severe toxicity occurs. ## Clinical Applications This CAR-T therapy is being investigated for: - CD19-positive hematologic malignancies - B-cell leukemias and lymphomas - Potentially other B-cell mediated conditions Like other CD19 CAR-T therapies, it works by recognizing and eliminating CD19-expressing cells, which includes both malignant and normal B cells. The therapy is manufactured from the patient's own T cells (autologous), which are collected through apheresis, genetically modified, expanded, and then reinfused back into the patient. The canonical name for this drug is "autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells" and it represents a specific configuration of CD19 CAR-T cell therapy with particular co-stimulatory domains and safety features.

Other names

Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cellsCD19-specific CAR-T cells (Tcm)CD19 CAR-T Cells Following HSCT for B-cell NHLCD-19 CAR-T Cells Following HSCT for B-cell NHLCD 19 CAR-T Cells Following HSCT for B-cell NHL